Full-Time

Free Energy Investigator

Posted on 6/18/2024

Tandem

Tandem

11-50 employees

AI-driven platform for pre-clinical drug discovery

No salary listed

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA + 1 more

More locations: New York, NY, USA

Category
Computational Biology
Biology & Biotech
Required Skills
Python
Requirements
  • PhD in Chemistry, Physics, or related discipline with 5+ years relevant industrial experience post-PhD (or MS in one of these fields with 7+ years of related experience)
  • Extensive hands-on experience in molecular dynamics simulations, free energy calculations, and enhanced sampling methods
  • Extensive programming experience (C/C++ and Python preferred) and familiarity with Linux and high-performance computing resources
  • Strong analytical and problem-solving skills
  • Excellent written and oral communication skills
  • Experience with computer-aided drug design, chemoinformatics, drug discovery, and machine learning
  • Highly motivated to develop computational methods for discovering better medicines
Responsibilities
  • Research and develop methods in molecular simulations and free energy calculations
  • Expand the applicability of free energy methods to different parts of the drug discovery process with novel approaches
  • Develop robust and turnkey free energy workflows with zero to minimal user intervention
  • Work closely with multidisciplinary teams to integrate free energy calculations into the discovery platform

TandemAI focuses on improving the drug discovery process for researchers, pharmaceutical companies, and academic institutions. Their main product, TandemViz, is a web-based platform that uses advanced computational tools and AI to simulate and visualize how drugs interact with proteins at the molecular level. This allows users to see drug-protein interactions in real-time through dynamic physics-based simulations. Unlike many competitors, TandemAI operates on a "Discovery as a Service" model, providing their tools and expertise through subscription fees and service contracts, making it easier for researchers to access these advanced technologies. The company's goal is to enhance the efficiency and success rate of pre-clinical drug candidates, ultimately leading to better treatment options for patients.

Company Size

11-50

Company Stage

Series A

Total Funding

$60M

Headquarters

New York City, New York

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven personalized medicine is rising, enhancing TandemAI's tailored drug discovery processes.
  • Collaborations with academic institutions offer TandemAI access to cutting-edge research.
  • AI-driven automation in wet labs can increase TandemAI's operational efficiency.

What critics are saying

  • Competitors may develop superior platforms, outpacing TandemAI's current offerings.
  • Venture capital reliance may pressure TandemAI for quick returns, affecting long-term goals.
  • Geopolitical tensions could impact TandemAI's operations in US and China markets.

What makes Tandem unique

  • TandemAI integrates AI with high-performance computation for drug discovery.
  • The company offers a turnkey solution combining computational tools and wet lab operations.
  • TandemViz provides web-based access to dynamic molecular simulations for drug-protein interactions.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↑ 6%
Tandem AI
Mar 28th, 2023
TandemAI Announces the Release of TandemViz™ 1.0 Web-based Graphical User Interface for Seamless Integration of Computational Analyses and Experimental Data

TandemAI today announced the release of TandemViz ™1.0, the company’s proprietary web-based platform that provides its growing roster of drug discovery clients with a user-friendly and collaborative graphical interface to TandemAI’s suite of computational tools.

Business Wire
Jan 17th, 2023
Tandemai Announces Appointment Of Alessandro Monge, Ph.D., As Chief Business Officer

SAN DIEGO & NEW YORK & SUZHOU & SHANGHAI--(BUSINESS WIRE)--TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced the appointment of Alessandro Monge, PhD, as Chief Business Officer. Dr. Monge has more than 20 years of experience in developing and deploying marketing strategies for computational technologies at established companies such as Schrödinger, as well as emerging companies, most recently at Iktos, where he was Senior Vice President and Head of US Operations.“Alessandro brings unique insights into how AI and computational tools can impact drug discovery and a wealth of experience in dealmaking with pharmaceutical and biotechnology companies,” said Jeff He, MBA, co-founder, and CEO of TandemAI. “In the CBO role, he will build on our success to date and drive TandemAI’s commercialization strategy.” He noted that TandemAI, founded in October, 2021, now has 200 employees in both the US and China, and currently serves more than 30 clients globally.“TandemAI’s integration of the most advanced computational technologies with medicinal chemistry and biology has great potential to bring unique value in drug discovery,” said Dr. Monge. “The company’s vision to dramatically lower the barrier to the world’s most advanced computational tools is inspiring and creates enormous opportunities for biotechnology and pharmaceutical partners to enhance and accelerate drug discovery through a streamlined, big data-driven process of ideation and testing.”Dr

Tandem AI
Aug 25th, 2022
Chengwei Capital invests into Tandemai in $25M

He noted that since TandemAI was established in late 2021 with $25M venture funding from OrbiMed and Chengwei Capital, the company has built a client roster of two dozen biotech companies.

BioSpace
Dec 22nd, 2021
TandemAI Announces $25 Million Seed & Pre-series A Financing Led by OrbiMed and Chengwei Capital

TandemAI today announced it has raised $25 million in Seed and pre-Series A financing to advance its proprietary computational platform and expansion of its wet lab operations.

INACTIVE